Clinical trials: Genome
Lymphoproliferative Disorders, Lymphoproliferative Disorder Following Transplantation
Liquid Biopsy to Enable Diagnostics and Monitoring for Immune-mediated Lymphoproliferative Disorders
Immune-mediated lymphoproliferative disorders (ILD), as per World Health Organization (WHO HAEM 5) classification, are rare conditions associated with a poor outcome.
- Trial name
- LIMPID (NCT05803616)
- Testing
- Liquid biopsy
- Where
- 6 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- University Hospital, Geneva
Hyperuricemia, Gout
Genetics of Hyperuricemia Therapy in Hmong
To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters…
- Trial name
- GOUT-H (NCT02371421)
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Minnesota
Lung Cancer
Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage
The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage.
- Trial name
- NCT05707585
- Testing
- Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)
- Where
- 3 sites in China
- Volunteers
- 2,064 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Non-small Cell Lung Cancer
PLAsma Genomic Testing in Patients With Advanced Non-Small Cell Lung Cancer: The PLAN Study
This is a multi-centre, prospective, translational study investigating the use of plasma genotyping for initial genomic testing in newly diagnosed advanced/locally advanced non-squamous NSCLC.
- Trial name
- PLAN (NCT05542485)
- Testing
- ctDNA liquid biopsy - Roche Avenio Assay
- Where
- 3 sites in Ireland
- Volunteers
- 97 people
- Sponsor
- Royal College of Surgeons, Ireland
Neoplasms, Germ Cell and Embryonal
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor)…
- Trial name
- NCT02679950
- Testing
- Next generation genome sequencing
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nasser Hanna
Pened Chest Surgery for Programmes Coronary Bypass
Mesenchymal Stem Cells: Alterations in Genome
The aim is to study small genetic alterations induced by cell culture in human mesenchymal stem cells in GMP condition.
- Trial name
- MESSAGE (NCT00836732)
- Testing
- harvest of a small bone marrow sample
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Nantes University Hospital
Inherited Retinal Dystrophy, Retinitis Pigmentosa
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models
Inherited retinal dystrophies (IRDs), a large group of heterogeneous and rare disorders, may result in irreversible bilateral visual loss and blindness.
- Conditions
- Inherited Retinal Dystrophy, Retinitis Pigmentosa, Macular Dystrophy
- Trial name
- NCT05793515
- Testing
- whole genome sequencing
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Superiore di Sanità
Prostate Cancer
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
- Trial name
- NCT01954004
- Where
- United States
- Volunteers
- 1,270 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Type2 Diabetes
Diabetes Research on Patient Stratification
The overarching goal of the IMI DIRECT (Innovative Medicines Initiative Diabetes Research on Patient Stratification) Consortium is the identification of biomarkers that aid therapeutic targeting in prediabetes (Study 1) or early…
- Trial name
- DIRECT (NCT03814915)
- Volunteers
- 3,049 people
- Sponsor
- Lund University
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
Locally Advanced or Metastatic NSCLC
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine kinase inhibitor-naïve NSCLC patients with…
- Trial name
- NCT03969823
- Testing
- Tagrisso
- Where
- 3 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Seoul National University Hospital
BCL2 Gene mRNA Overexpression
Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study
Multiple biomarker development through validation of useful markers generated by next generation bio-data based genome research and cohort study
- Trial name
- miRNA_Chip (NCT02807896)
- Where
- South Korea
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- CHANGHEE LEE
Non-Immune Hydrops Fetalis
Uncovering the Etiologies of Non-immune Hydrops Fetalis
Non-immune hydrops fetalis (NIHF) is diagnosed on prenatal ultrasound when abnormal fluid collections are seen in the fetus. NIHF carries significant risks of stillbirth, preterm birth, and postnatal morbidity and mortality…
- Trial name
- NCT05528796
- Testing
- Whole genome sequencing
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of California, San Francisco
Cancer, Immunotherapy
A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.
The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs)…
- Conditions
- Cancer, Immunotherapy, PD-1, PD-L1
- Trial name
- PROWES (NCT06635954)
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Oxford Biodynamics Inc.
Breast Cancer, Prostate Cancer
Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with…
- Conditions
- Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
- Trial name
- NCT05179824
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI
Non-small Cell Lung Carcinoma, Urothelial Carcinoma
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
With the increased availability of next-generation sequencing, oncologists are starting to incorporate genomic profiling into routine care of cancer patients.
- Conditions
- Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
- Trial name
- NCT02795156
- Testing
- Afatinib, Regorafenib, Cabozantinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- SCRI Development Innovations, LLC
Staphylococcus Epidermidis Positive Blood Culture
Invasive Markers of Staphylococcus Epidermidis
The purpose of the study is to identify biomarkers allowing the distinction between invasive and non-invasive strains of Staphylococcus epidermidis.
- Trial name
- SepiNGS (NCT03374371)
- Testing
- high-throughput sequencing
- Where
- France
- Volunteers
- 320 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Unresectable or Metastatic Solid Malignancy
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced…
- Trial name
- MyTACTIC (NCT04632992)
- Testing
- Entrectinib, Inavolisib, Alectinib
- Where
- 38 sites in United States
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Bone and Soft Tissue Tumors
Molecular and Clinical Studies of Bone and Soft Tissue Tumors
The goal of this observational study is to learn whether tumors of bone and soft tissue can be sorted into groups by their genes. Today these tumors are named mainly by how they look under a microscope.
- Trial name
- NCT07822204
- Where
- Sweden
- Volunteers
- 50,000 people
- Sponsor
- Karolinska Institutet
Neuroendocrine Carcinoma, Grade 3
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO grade 3) as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify…
- Trial name
- MS100070-0177 (NCT03147404)
- Testing
- Avelumab
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.